6.2 Opioid Prescribing Limits, MME Calculations & Acute Pain Restrictions

Mississippi Opioid Prescribing Rules

Mississippi State Board of Medical Licensure opioid rules govern licensed medical prescribers and supply important context for a pharmacist assessing an opioid prescription. They do not create every rule for every practitioner, and they should not be converted into a fabricated universal seven-day dispensing cap.

Acute noncancer, nonterminal pain

For acute pain not associated with cancer or terminal illness, the current rule directs the prescriber to use the lowest effective dose of an immediate-release opioid. A supply greater than three days is discouraged, and the initial prescription may not exceed a ten-day supply. Extended-release or long-acting opioids are not used for this acute framework.

When additional opioid treatment is necessary, the rule permits an additional sequential prescription of up to ten days with the required clinical basis and documentation. Further supply requires the evaluation and documentation specified by the current rule rather than automatic serial 10-day prescriptions. “Three days discouraged” is not the same as a three-day hard cap; “ten days maximum” is not the outdated claim of seven days for ordinary acute pain.

The pharmacist should identify diagnosis and context, formulation, days’ supply, prior exposure, concurrent sedatives, prescriber authority, and PMP history. A prescription inconsistent with the rule is a red flag to resolve, not permission to rewrite the prescription or diagnose the patient.

Chronic noncancer pain and MME

For chronic opioid therapy, current Mississippi medical-board standards use morphine milligram equivalents as risk thresholds. Prescribers should strive to keep dosage at or below 50 MME/day, avoid dosage of 90 MME/day or more or provide significant justification, and refer a patient receiving more than 100 MME/day to a pain specialist as the rule provides.

These values are not interchangeable. They also are not an automatic federal legal ceiling and do not establish that a prescription at 89 MME is safe. Evaluate total opioid exposure, tolerance, diagnosis, function, duration, interactions, overdose history, sleep-disordered breathing, renal/hepatic status, and concurrent benzodiazepines or other depressants.

Use current conversion factors and treat the result as an estimate. Current CDC factors include hydromorphone 5, tramadol 0.2, and a uniform methadone factor 4.7 in the CDC implementation guide. Older tables using hydromorphone 4, tramadol 0.1, or tiered methadone factors can materially miscalculate current examples. Fentanyl transdermal uses mcg/hour multiplied by 2.4, not milligrams per day multiplied like an oral product.

Risk mitigation

The medical-board rules require appropriate history, examination, treatment planning, informed discussion, monitoring, PMP use, toxicology or agreements when indicated, and documentation according to the patient and therapy. They discourage dangerous combinations and support tapering or referral when risks outweigh benefits.

Current Mississippi text should not be overstated as a universal command that every opioid prescription at a particular MME must be accompanied by naloxone. Naloxone is sound risk mitigation for many patients and may be dispensed under the current statewide standing order, but distinguish recommended or patient-specific care from a blanket legal co-prescribing mandate.

Pharmacist responsibility

A pharmacist does not enforce the prescriber rule by silently changing days’ supply, dosage, or formulation. Query the PMP when required, recognize red flags, communicate with the practitioner, document the resolution, counsel on dose, storage, sedation, interactions, overdose recognition, naloxone, and disposal, and refuse if legitimate medical purpose or safety concerns remain unresolved.

Exam method

For acute pain remember immediate release, more than three days discouraged, initial maximum ten days, with a documented sequential up-to-ten-day pathway. For chronic therapy remember strive ≤50, avoid/significantly justify ≥90, refer >100. Then apply the correct current MME factor and keep prescriber duties distinct from the pharmacist’s corresponding responsibility.

Acute and chronic examples

An immediate-release opioid for five days is not automatically unlawful: more than three days is discouraged, but the initial hard ceiling is ten days. The prescriber should document why the amount is appropriate. A 14-day extended-release product for routine acute back strain presents both formulation and quantity concerns and requires resolution.

For chronic therapy at 96 MME/day, ask for the significant justification and risk-monitoring plan; the 90 threshold is not a pharmacist-created automatic void. At 110 MME/day, the current rule’s pain-specialist referral requirement becomes relevant. In either case, overlapping benzodiazepines, prior overdose, early fills, and loss of tolerance can matter more than a single calculated number. Verify the factor, route, and daily dose before applying the threshold.